Literature DB >> 27900038

Antitumor effects and mechanisms of Ganoderma extracts and spores oil.

Chun Chen1, Peng Li1, Ye Li2, Guan Yao3, Jian-Hua Xu1.   

Abstract

Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC50) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6%, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9%, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.

Entities:  

Keywords:  Ganoderma extracts; Ganoderma spores oil; cell cycle; cyclin D1; topoisomerase I and II; tumor

Year:  2016        PMID: 27900038      PMCID: PMC5104053          DOI: 10.3892/ol.2016.5059

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Authors:  K Hofland; B O Petersen; J Falck; K Helin; P B Jensen; M Sehested
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

2.  Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.

Authors:  Anna Kruczynski; Jean-Marc Barret; Benoît Van Hille; Nathalie Chansard; Jackie Astruc; Yoann Menon; Carole Duchier; Laurent Créancier; Bridget T Hill
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

3.  Ganoderma lucidum mycelia enhance innate immunity by activating NF-kappaB.

Authors:  Mei-Chun Kuo; Ching-Yi Weng; Choi-Lan Ha; Ming-Jiuan Wu
Journal:  J Ethnopharmacol       Date:  2005-09-15       Impact factor: 4.360

4.  Effects of Ganoderma lucidum polysaccharides on proliferation and cytotoxicity of cytokine-induced killer cells.

Authors:  Xiao-ling Zhu; Zhi-bin Lin
Journal:  Acta Pharmacol Sin       Date:  2005-09       Impact factor: 6.150

5.  GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells.

Authors:  I-Lun Hsin; Chu-Chyn Ou; Tzu-Chin Wu; Ming-Shiou Jan; Ming-Fang Wu; Ling-Yen Chiu; Ko-Huang Lue; Jiunn-Liang Ko
Journal:  Autophagy       Date:  2011-08-01       Impact factor: 16.016

6.  Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.

Authors:  Angelica Mariani; Alexandra Bartoli; Mandeep Atwal; Ka C Lee; Caroline A Austin; Raphaël Rodriguez
Journal:  J Med Chem       Date:  2015-05-20       Impact factor: 7.446

7.  Lanostane triterpenoids from Ganoderma hainanense J. D. Zhao.

Authors:  XingRong Peng; JieQing Liu; JianJun Xia; CuiFang Wang; XuYang Li; YuanYuan Deng; NiMan Bao; ZhiRun Zhang; MingHua Qiu
Journal:  Phytochemistry       Date:  2014-10-31       Impact factor: 4.072

8.  Ganoderic acid X, a lanostanoid triterpene, inhibits topoisomerases and induces apoptosis of cancer cells.

Authors:  Chyi-Hann Li; Pei-Yu Chen; Ue-Min Chang; Lou-Sing Kan; Woei-Horng Fang; Keh-Sung Tsai; Shwu-Bin Lin
Journal:  Life Sci       Date:  2005-02-25       Impact factor: 5.037

9.  Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells.

Authors:  Kee-jong Hong; Dale M Dunn; Chwan-Li Shen; Barbara C Pence
Journal:  Phytother Res       Date:  2004-09       Impact factor: 5.878

10.  Immunomodulatory effect of Ganoderma atrum polysaccharide on CT26 tumor-bearing mice.

Authors:  Shenshen Zhang; Shaoping Nie; Danfei Huang; Wenjuan Li; Mingyong Xie
Journal:  Food Chem       Date:  2012-09-18       Impact factor: 7.514

View more
  1 in total

Review 1.  Traditional uses, chemical components and pharmacological activities of the genus Ganoderma P. Karst.: a review.

Authors:  Li Wang; Jie-Qing Li; Ji Zhang; Zhi-Min Li; Hong-Gao Liu; Yuan-Zhong Wang
Journal:  RSC Adv       Date:  2020-11-18       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.